相关实验视频

Updated: Jun 14, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.7K

简要报告:在转移性NSCLC中使用Pembrolizumab单疗法进行前性试验,评估循环瘤DNA作为反应的替代生物标志物

Iris van 't Erve1,2, Isabelle Blanchard3, Judy Y Pagtama4

  • 1Stanford Cancer Institute, Stanford University, Stanford, California.

JTO clinical and research reports
|September 2, 2025
PubMed
概括

在接受免疫检查点抑制剂的转移性非小细胞肺癌 (NSCLC) 患者中,循环瘤DNA (ctDNA) 可以预测治疗反应. 早期的ctDNA变化可以准确预测放射性反应和存活率,从而为没有反应的人提供及时的干预.

关键词:
生物标志物液体活检肺部癌症在 NSCLC翻译研究ctDNA 在

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K

相关概念视频

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...